Considerations for the Use of Cytokine-Secreting Tumor Cell Preparations for Cancer Treatment

References

• Gibaldi M. Human gene therapy. Pharmacotherapy 1993; 13(2)79–87
   PubMed Web of Science ®Google Scholar
• Oettgen H F, Old L. I. The history of cancer immunotherapy. Biological Therapy of Cancer, V T DeVita, S Hellmann, S A Rosenberg. Lippincott, Philadelphia 1991; 87–119
   Google Scholar
• Livingston P O. Active specific immunotherapy in treatment of patients with cancer. Immunology and Allergy Clinics of North America, H F Oettgen. WB Sauders, London 1991; 3329–3335
   Google Scholar
• Rosenberg S A, Lotze M T, Muul L M, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316(15)889–897
   PubMed Web of Science ®Google Scholar
• Rosenberg S A. Immunotherapy of cancer using interleukin-2: Current status and future prospects. Immunol Today 1988; 9(2)58–62
   PubMedGoogle Scholar
• Alexander R B, Rosenberg S A. Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persit long-term in vivo as functional memory T lymphocytes. J Immunother 1991; 10(6)389–397
   PubMed Web of Science ®Google Scholar
• Zinkernagel R M, Doherty P C. MHC-restricted cytotoxic T cell: Studies on the role of polymorphic major transplantation antigens determining T cell restriction-specificity, function and responsiveness. Adv Immunol 1979; 27: 51–106
   PubMedGoogle Scholar
• Townsend A, Bodmer H. Antigen recognition by class I restricted T lymphocytes. Annu Rev Immunol 1989; 7: 601–624
   PubMed Web of Science ®Google Scholar
• Zinkernagel R M, Callahan G N, Althage A, et al. The lymphoreticular system in triggering virus plus self-specific cytotoxic T-cells: Evidence for T help. J Exp Med 1978; 147: 897–911
   PubMed Web of Science ®Google Scholar
• van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 1982; 79: 4718–4722
   PubMed Web of Science ®Google Scholar
• Thompson L. At age 2, gene therapy enters a growth phase. Science 1992; 258: 744–746
   PubMed Web of Science ®Google Scholar
• Roe T, Reynolds T C, Yu G, et al. Integration of murine leukemia virus DNA depends on mitosis. EMBOJ 1993; 12(5)2099–2108
   PubMed Web of Science ®Google Scholar
• Blacklow N R, Hoggan M D, Kapikian A Z, et al. Epidemiology of adeno-associated virus infection in a nursery population. Am J Epidemiol 1968; 88: 368–378
   PubMed Web of Science ®Google Scholar
• Berns K I. Parvovirus replication. Microbiol Rev 1990; 54(3)316–329
   PubMedGoogle Scholar
• Lebkowski J S, Page K, McNally M M, et al. Adeno-associated virus: A vector for high efficiency transduction of primary cells. Second International Conference on Gene Therapy of Cancer. 1993; A23–11
   Google Scholar
• Nevins J R. Mechanisms of activation of early viral transcription by the adenovirus. El A gene product. Cell 1981; 26: 213–220
   PubMed Web of Science ®Google Scholar
• Rosenfeld M A, Yoshimura K, Trapnell B C, et al. In vivo transfer of the human cystic fibrosis transmembrance conductance regulator gene to the airway epithelium. Cell 1992; 68(1)143–155
   PubMed Web of Science ®Google Scholar
• Jaffee H A, Danel C, Longenecker G, et al. Adenovirus mediated in vivo gene transfer and expression in normal rat liver. Nature Genet 1992; l(5)372–378
   Google Scholar
• La Salle G L, Roberty J J, Berrard R S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259: 988–990
   PubMed Web of Science ®Google Scholar
• Malone R, Feigner P, Velma I. Cationic liposome mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86: 6077–6081
   PubMed Web of Science ®Google Scholar
• Steward M J, Plautz G E, Del Buono L, et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity of mice. Hum Gene Ther 1992; 3: 267–275
   PubMed Web of Science ®Google Scholar
• William R S, Johnston S A, Riedy M, et al. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci USA 1991; 88(7)2726–2730
   PubMed Web of Science ®Google Scholar
• Ulmer J B, Donnelly J J, Parker S E, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745–1749
   PubMed Web of Science ®Google Scholar
• Philip R, Lebkowsky J S, Brunette E, et al. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated viral plasmid complexed to cationic liposomes. Mol Cell Biol 1994; 14: 2411–2418
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicy and induces protective immunity. J Exp Med 1990; 172: 1217–1224
   PubMed Web of Science ®Google Scholar
• Fearon E R, Pardoll D M, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma CI300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86: 9456–9460
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated y-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990; 50: 7820–7825
   PubMed Web of Science ®Google Scholar
• Hewitt H B, Blake E R, Walder A S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 1976; 33: 241–259
   PubMed Web of Science ®Google Scholar
• Gastl G, Finstad C L, Guarini A, et al. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 1992; 52(22)6229–6236
   PubMed Web of Science ®Google Scholar
• Fidler I J. Critical factors in the biology of human cancer metastasis: Twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res 1990; 50: 6130–6138
   PubMed Web of Science ®Google Scholar
• Bubenick J, Simova J, Jandlova T. Immunotherapy of cancer using local administration of lympoid cells transformed by II-2 cDNA and constitutively producing II-2. Immunol Lett 1989; 23: 287–292
   Web of Science ®Google Scholar
• Ley V., Langlade-Demoyen P, Kourilsky P, et al. Interleukin 2-dependent activation of tumor specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991; 21: 851–854
   PubMed Web of Science ®Google Scholar
• Cavallo F, Giovarelli M, Gulino A, et al. Role of neutrophils and CD4 T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992; 149(11)3627–3635
   PubMed Web of Science ®Google Scholar
• Restifo N, Spiess P, Karp S, et al. A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ cells against the wild-type tumor: Correlation with antigen presentation capability. J Exp Med 1992; 175: 1423–1431
   PubMed Web of Science ®Google Scholar
• Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene modifed tumor vaccines. Cancer Res 1994; 54: 3516–3520
   PubMed Web of Science ®Google Scholar
• Tepper R I, Pattengale P K, Leder P. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Tepper R I, Coffmann R L, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257: 548–551
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Qin Z, Liberia W, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J Exp Med 1991; 173: 1047–1052
   PubMed Web of Science ®Google Scholar
• Teng M N, Park B H, Koeppen H KW, et al. Long term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 1991; 88: 3535–3539
   PubMed Web of Science ®Google Scholar
• Colombo M P, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173(41)889–897
   PubMedGoogle Scholar
• Golumbek P T, Lazenby A J, Levitsky H I, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716
   PubMed Web of Science ®Google Scholar
• Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679–3686
   PubMed Web of Science ®Google Scholar
• Aoki T, Tashiro K, Miyatake S, et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 1992; 89: 3850–3854
   PubMed Web of Science ®Google Scholar
• Hock H, Dorsch M, Diamantstein T, et al. Interleukin 7 induces CD4 T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291–1298
   PubMed Web of Science ®Google Scholar
• Tahara H, Zeh H, Storkus W, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182–189
   PubMed Web of Science ®Google Scholar
• Asher A L, Mule J J, Kasid A, et al. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991; 146(9)3227–3234
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-marcophage colony stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543
   PubMed Web of Science ®Google Scholar
• Porgador A, Tzehoval E, Vadai E, et al. Immunotherapy via gene therapy: Comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6. or interferon-y genes. γ Im-munother 1993; 14: 191–201
   Google Scholar
• Gansbacher B, Rosenthal F M, Guarini A, et al. Retroviral vectors carrying both the interleukin-2 and interferon-gamma gene induce potent antitumor responses in murine tumors. Proc Annu Meet Am Assoc Cancer Res 1992; 33: A2095
   Google Scholar
• Vieweg J, Rosenthal F, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modifed tumor vaccines. Cancer Res 1994; 54: 1760–1765
   PubMed Web of Science ®Google Scholar
• Vieweg J, Heston W DW, Gilboa E, et al. An experimental model simulating local recurrence and pelvic lymph node metastasis following orthotopic induction of prostate cancer cells. Prostate 1994; 24: 291–298
   PubMed Web of Science ®Google Scholar
• Russel S J, Eccles S A, Flemming C L, et al. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1992; 47: 244–251
   Web of Science ®Google Scholar
• Connor J, Bannerij R, Saito S, et al. Regression of bladder tumors on mice treated with interleukin-2 gene-modified tumor cells. J Exp Med 1993; 177: 1127–1134
   PubMed Web of Science ®Google Scholar
• Esumi N, Hunt B, Itaya T, et al. Reduced tumorigenicity of murine tumor cells secreting y-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res 1991; 51: 1185–1189
   PubMed Web of Science ®Google Scholar
• Maruguchi Y, Toda K-I, Fuji K, et al. Survival period of tumor-bearing mice is prolonged after the interferon-gamma producing gene transfer. Cancer Lett 1991; 60: 41–49
   PubMed Web of Science ®Google Scholar
• Bruggen P VD, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–1647
   PubMed Web of Science ®Google Scholar
• Jaffee E M, Dranoff G, Cohen L K, et al. High Efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53: 2221–2226
   PubMed Web of Science ®Google Scholar
• Moreno J G, Croce C M, Fischer R, et al. Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 1992; 52(21)6110–6112
   PubMed Web of Science ®Google Scholar
• Greene F L. Laparoscopy in malignant disease. Surg Clin North Am 1992; 72(5)1125–1137
   PubMed Web of Science ®Google Scholar
• Riddell S R, Watanabe K S, Goodrich J M, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257: 238–241
   PubMed Web of Science ®Google Scholar
• Chen L, Ashe S, Brady W A, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093–1102
   PubMed Web of Science ®Google Scholar
• Townsend S E, Allison J P. Tumor rejection after direct costimulation of CD8 T cells by B7-transfected melanoma cells. Science 1993; 259: 368–370
   PubMed Web of Science ®Google Scholar
• Schwartz R H. Costimulation of T lymphocytes: The role of CD28. CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065–1068
   PubMed Web of Science ®Google Scholar
• Fidler I J. Macrophages and metastasis–A biological approach to cancer therapy. Cancer Res 1985; 45: 4714–4726
   PubMed Web of Science ®Google Scholar
• Steinmann R M. The dendritic cell system and its role in im-munogenicity. Annu Rev Immunol 1991; 9: 271–296
   PubMed Web of Science ®Google Scholar